List of Excipients in Branded Drug TYENNE

TYENNE Excipient Strategy and Commercial Opportunities: Formulation, Biosimilar Competition, and Patent Risk

Last updated: August 9, 2026

TYENNE, Fresenius Kabi’s tocilizumab biosimilar, creates commercial opportunities across intravenous and subcutaneous delivery, but its excipient strategy is constrained by biosimilarity, protein stability, device compatibility, and cold-chain economics. The main value opportunities are not novel excipient ownership alone. They are lower-cost manufacturing, improved fill-finish efficiency, differentiated delivery systems, supply reliability, and formulation or device patents that support market access after reference-product exclusivity expires.

What is TYENNE and which formulations does it use?

TYENNE is a biosimilar to Roche’s ACTEMRA or RoActemra, whose active ingredient is tocilizumab, an interleukin-6 receptor antagonist. The product has intravenous and subcutaneous presentations. The European Commission authorized TYENNE in 2024, and the U.S. Food and Drug Administration approved tocilizumab-aazg in 2025 under the U.S. biosimilar pathway.[1,2]

TYENNE formulation and excipient profile

Public product information identifies different excipient systems for the intravenous and subcutaneous presentations.

Presentation	Active concentration	Principal excipients	Commercial function
IV concentrate	20 mg/mL	Polysorbate 80, sucrose, disodium phosphate dodecahydrate, sodium dihydrogen phosphate monohydrate, water for injection	Protein stabilization, tonicity, pH control, aggregation control
SC solution	162 mg/0.9 mL	L-arginine, histidine, histidine hydrochloride monohydrate, polysorbate 80, water for injection	High-concentration protein stabilization, buffering, viscosity and injection-tolerability management

The exact presentation, container, and excipient requirements should be assessed against the applicable U.S. Prescribing Information and European product information because regional labels can differ in device configuration and presentation.[1,2]

Why TYENNE uses different IV and SC excipient systems

The intravenous product is diluted before administration. Its formulation can therefore rely on a conventional protein-stabilizing system containing sucrose, phosphate buffer, and polysorbate 80.

The subcutaneous product must deliver a concentrated antibody dose in a small injection volume. Its formulation must manage higher protein concentration, local injection tolerability, viscosity, aggregation, and syringe or autoinjector compatibility. Amino-acid excipients such as arginine and histidine can support protein stability while permitting a high-concentration liquid formulation.

What does each TYENNE excipient do?

Polysorbate 80

Polysorbate 80 reduces adsorption of tocilizumab to glass, plastic, elastomeric components, and other interfaces. It also limits agitation-induced aggregation during manufacturing, transport, and administration.

The principal risks are oxidation, hydrolysis, peroxide formation, and interaction with the protein or container closure. These risks create commercial opportunities for:

• Low-peroxide polysorbate 80 grades
• Tightly controlled compendial and noncompendial specifications
• Improved supplier qualification
• Oxidative impurity testing
• Alternative surfactant screening
• Stabilized or higher-purity surfactant systems

A biosimilar manufacturer cannot change surfactant identity or concentration solely for cost reasons without demonstrating product quality comparability. A material change may affect aggregation, subvisible particles, charge variants, potency, immunogenicity, or device performance.

Sucrose

Sucrose is used in the IV formulation as a stabilizer and tonicity contributor. It can protect the antibody during freezing, thawing, concentration, and storage. Its commercial value is primarily operational rather than exclusivity-based.

Potential development opportunities include:

• Sucrose grade and impurity control
• Reduced particulate generation
• Improved freeze-thaw robustness
• Lower-cost validated supply
• Optimized formulation osmolality

Sucrose is widely used and generally provides limited standalone patent protection. Its strategic value comes from its concentration, interaction with other excipients, and role in a validated manufacturing process.

Phosphate buffer

Disodium phosphate and sodium dihydrogen phosphate establish and maintain formulation pH. Tocilizumab stability depends on a controlled pH range because pH can affect aggregation, deamidation, oxidation, charge heterogeneity, and potency.

Commercial opportunities include buffer optimization, reduced pH drift, improved compatibility with the container closure, and formulation robustness after dilution into infusion bags. A formulation patent may claim a specific pH range, buffer concentration, stabilizer ratio, or storage profile rather than phosphate alone.

L-arginine and histidine

The subcutaneous formulation uses arginine and histidine-based excipients to support high-concentration antibody stability. Arginine can reduce protein-protein interactions and aggregation in concentrated biologic solutions. Histidine provides buffering capacity in a physiologically relevant range.

These excipients can influence:

• Viscosity
• Opalescence
• Aggregation
• Local injection tolerability
• Protein adsorption
• Freeze-thaw stability
• High-concentration manufacturability

The strongest commercial opportunity is not the individual amino acid. It is the optimized combination and its integration with the delivery device.

What excipient strategy is commercially attractive for TYENNE?

The most attractive strategy is a platform approach that preserves the approved formulation while improving supply, manufacturability, and delivery economics.

Strategy 1: Preserve the established excipient architecture

The lowest regulatory-risk approach is to retain the established IV and SC excipient systems and compete through:

• Higher manufacturing yield
• Lower fill-finish cost
• Reduced batch failure
• Improved vial utilization
• Better cold-chain logistics
• Competitive procurement pricing
• Reliable supply during shortages

This approach is commercially important because biosimilar purchasers generally prioritize comparable efficacy and safety, total treatment cost, supply continuity, and administration convenience.

Strategy 2: Optimize the subcutaneous formulation

The SC presentation offers greater differentiation potential than the IV product. It requires a concentrated formulation and may support prefilled syringes or autoinjectors.

Potential improvements include:

• Lower injection force
• Reduced viscosity
• Lower injection volume
• Better syringeability
• Longer in-use stability
• Greater resistance to agitation
• Improved device compatibility
• Reduced silicone-oil or tungsten-related particles

These improvements may support device patents, formulation patents, or product-line extensions. They must remain within the evidence package supporting biosimilarity and applicable regulatory requirements.

Strategy 3: Develop excipient supplier control

Polysorbate 80 is a critical raw material because its degradation profile can affect biologic quality. A manufacturer can reduce supply risk by qualifying multiple suppliers, controlling peroxide levels, setting particle specifications, and implementing incoming-material analytics.

This strategy can produce a durable cost advantage even when the final formulation is not patent-protected. It also reduces exposure to batch failures and formulation instability.

Strategy 4: Improve container-closure compatibility

TYENNE’s commercial performance depends on the interaction among the formulation, vial, syringe, needle, stopper, plunger, and autoinjector components.

Relevant development areas include:

• Low-extractables elastomers
• Silicone-control strategies
• Reduced protein adsorption
• Break-loose and glide-force optimization
• Low-particle syringe components
• Improved light protection
• Container-closure integrity
• Shorter inspection and release cycles

These features can support device or packaging claims even where the excipients are conventional.

What patents protect TYENNE and its excipient strategy?

TYENNE is a biologic biosimilar, so its intellectual-property position is different from a conventional small-molecule generic.

Does TYENNE have Orange Book-listed formulation patents?

No conventional Orange Book analysis applies to TYENNE as a BLA-approved biologic. The relevant U.S. framework is the Biologics Price Competition and Innovation Act, including the Purple Book and BPCIA patent-exchange and litigation procedures.[3,4]

ACTEMRA’s relevant intellectual property can include:

• Composition-of-matter and antibody patents
• Cell-line and production-process patents
• Formulation patents
• Subcutaneous delivery patents
• Method-of-use patents
• Device and packaging patents
• Regulatory exclusivity

The practical risk for TYENNE is assessed through the reference product’s patent disclosures, BPCIA exchanges, litigation history, settlement terms, and any applicable pediatric or regulatory exclusivity.

Are the excipients themselves patentable?

Most individual excipients in TYENNE are established pharmaceutical materials and are unlikely to provide meaningful standalone exclusivity. Commercially relevant protection is more likely to arise from:

• Specific excipient ratios
• Defined pH and osmolality ranges
• High-concentration tocilizumab formulations
• Reduced aggregation or particle formation
• Long-term storage conditions
• Device-formulation combinations
• Container-closure systems
• Manufacturing processes that preserve quality attributes

A company seeking additional protection should claim the complete formulation or delivery system, not simply polysorbate 80, sucrose, arginine, or histidine.

When does TYENNE lose exclusivity and face generic or biosimilar competition?

TYENNE is already a biosimilar entrant rather than the originator. Its commercial position depends on the remaining exclusivity of ACTEMRA, the timing of other tocilizumab biosimilars, and regulatory approvals in each market.

Exclusivity issue	Relevance to TYENNE
Reference-product biologic exclusivity	Determines the earliest biosimilar approval timing in the U.S.
Reference formulation patents	May restrict certain formulations or delivery configurations
Method-of-use patents	Can affect specific indications or labeling
Device patents	May affect autoinjector or prefilled-syringe competition
TYENNE regulatory exclusivity	Generally does not create small-molecule-style generic exclusivity
Biosimilar interchangeability	Affects substitution and payer uptake in the U.S.
Regional patent settlements	Can create market-entry dates that differ by country

The primary competitive threat is not a conventional generic tablet or injectable. It is a subsequent tocilizumab biosimilar with lower acquisition cost, interchangeable status, broader device availability, or stronger payer contracting.

Which companies are challenging the ACTEMRA market?

The competitive landscape includes Fresenius Kabi through TYENNE and other manufacturers developing or commercializing tocilizumab biosimilars across global markets. Competition is likely to develop around:

• Hospital infusion contracts
• Specialty pharmacy distribution
• Government tenders
• Subcutaneous self-administration
• Autoinjector availability
• Interchangeability
• Manufacturing scale
• Global supply reliability

In Europe, biosimilar competition is shaped by national tendering and hospital procurement. In the U.S., pharmacy benefit design, medical-benefit reimbursement, formulary placement, and state substitution rules will influence uptake.

What are the FDA regulatory issues for TYENNE?

TYENNE’s FDA pathway is the 351(k) biosimilar route. The sponsor must demonstrate that the product is highly similar to the reference product and has no clinically meaningful differences in safety, purity, and potency.[3]

Excipient changes are permitted in principle but create comparability obligations. The most sensitive attributes include:

• Aggregation
• Charge variants
• Glycosylation
• Binding activity
• Potency
• Subvisible particles
• Immunogenicity risk
• Stability
• Extractables and leachables
• Device performance

An excipient strategy that changes the reference-like formulation may increase analytical, clinical, device, and regulatory costs. The economic return must exceed the risk of delay or a narrower approval package.

What commercial opportunities exist beyond the approved TYENNE product?

Excipient supply and analytical services

Specialty suppliers can target TYENNE and other monoclonal-antibody products with:

• High-purity polysorbate 80
• Low-peroxide surfactants
• Amino-acid excipients
• Protein-stability screening
• Oxidation and hydrolysis testing
• Particulate characterization
• Container-closure compatibility studies

These opportunities are recurring because biologic manufacturers require continuous raw-material qualification and lifecycle management.

Contract development and manufacturing

CDMOs can capture value through:

• Tocilizumab drug-substance manufacturing
• Aseptic fill-finish
• Prefilled-syringe assembly
• Autoinjector assembly
• Stability studies
• Device combination-product testing
• Regional packaging
• Cold-chain distribution

The strongest demand is likely for flexible facilities that can support both vials and high-volume SC presentations.

Device differentiation

The SC formulation may support commercial differentiation through:

• Autoinjectors
• Prefilled syringes
• Low-force injection systems
• Human-factors improvements
• Home-administration support
• Reduced preparation time
• Digital adherence tools linked to administration records

Device patents may provide more practical differentiation than excipient patents because they can influence patient and payer preference.

Geographic expansion

Tocilizumab demand spans rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis, cytokine release syndrome, and other approved or locally authorized uses. Market opportunities vary by:

• National biosimilar substitution rules
• Hospital tender structures
• Availability of reference-product rebates
• Cold-chain infrastructure
• Local manufacturing requirements
• Regulatory reliance pathways
• Access to biologic treatment

A formulation approved in Europe may require separate device, labeling, or presentation work for the U.S. and other jurisdictions.

How strong is TYENNE’s patent and commercial position?

TYENNE’s strongest defensible advantages are likely to be regulatory approval, manufacturing scale, supply continuity, device execution, and contracting rather than ownership of basic excipient composition.

Asset	Relative commercial strength
Conventional IV excipient system	Low standalone IP differentiation
High-concentration SC formulation	Moderate differentiation potential
Polysorbate 80 supply controls	High operational value, limited exclusivity
Prefilled syringe or autoinjector	Moderate to high device value
Manufacturing process	Moderate, depending on claims and trade secrets
Regulatory approval	High near-term market-access value
Interchangeability, if obtained	Potentially high U.S. substitution value
Global tender capability	High commercial value in Europe and emerging markets

Key Takeaways

• TYENNE is a tocilizumab biosimilar with IV and SC presentations.
• The IV formulation uses polysorbate 80, sucrose, phosphate buffers, and water for injection.
• The SC formulation uses polysorbate 80, arginine, histidine-based buffering, and water for injection.
• Individual excipients offer limited standalone patent value.
• The strongest formulation opportunities involve high-concentration SC stability, viscosity, aggregation control, and device compatibility.
• Polysorbate 80 quality and degradation control are important manufacturing and supply-chain issues.
• U.S. patent analysis should focus on BPCIA disclosures, Purple Book status, formulation claims, method-of-use claims, and device patents rather than the Orange Book.
• Commercial value is likely to come from lower cost, supply reliability, subcutaneous delivery, device differentiation, and payer contracting.
• The main competitive risk is additional tocilizumab biosimilar entry, not a conventional small-molecule generic.

FAQs

Does TYENNE contain polysorbate 80?

Yes. Public product information identifies polysorbate 80 in both the IV and SC TYENNE formulations.[1,2]

Is TYENNE interchangeable with ACTEMRA in the United States?

Biosimilar approval and interchangeability are separate regulatory determinations. Substitution depends on the FDA-approved labeling, Purple Book designation, state law, and payer policy.[3,4]

Can TYENNE be reformulated with polysorbate 20?

A switch to polysorbate 20 would require extensive analytical and regulatory comparability work. It could alter aggregation, oxidation, particle formation, stability, and immunogenicity risk.

Which TYENNE presentation has the greater commercial opportunity?

The SC presentation generally offers more differentiation potential because it can support home administration, prefilled syringes, autoinjectors, and formulation-device innovation. The IV product may compete more directly on manufacturing cost and hospital tenders.

Are TYENNE’s excipients likely to create blocking patent risk?

The individual excipients are unlikely to create significant blocking rights. Risk is more likely to arise from claims covering tocilizumab formulation parameters, high-concentration stability, delivery devices, container systems, manufacturing processes, or indication-specific use.

References

1. European Medicines Agency. (2024). Tyenne: EPAR product information. https://www.ema.europa.eu/en/medicines/human/EPAR/tyenne

2. Fresenius Kabi. (2025). TYENNE prescribing information and product information. https://www.fresenius-kabi.com

3. U.S. Food and Drug Administration. (2025). TYENNE (tocilizumab-aazg) prescribing information. https://www.accessdata.fda.gov

4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov

5. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars-and-interchangeable-products